


Recurrence after surgery: what the evidence shows

Intismeran autogene + pembrolizumab versus pembrolizumab | Evidence reviewed 13 September 2026

A KEYNOTE-942

Randomized, open-label Phase 2b · 157 patients
Resected high-risk stage III/IV melanoma · Median five-year follow-up



A relative hazard comparison

The estimate concerns time to recurrence or death.
It is not a 49-percentage-point absolute improvement
and does not mean 49% of patients were cured.

B INTerpath-001

Randomized, double-blind Phase 3
1,137 patients · Resected stage IIB–IV melanoma

RFS endpoint met

Primary endpoint

DMFS endpoint met

Key secondary endpoint

Overall survival follow-up

Study continues

19 August 2026 topline release

Numerical Phase 3 effect sizes and
confidence intervals were not disclosed.
Do not substitute the Phase 2b estimate.

Investigational therapy. Illustrated target-cell death is not clinical evidence of cure or guaranteed tumor clearance.

Safety: pembrolizumab can cause severe or fatal immune-mediated adverse reactions. The sponsor reported no new safety signals in the Phase 3 topline release; that is not a substitute for the full safety dataset or prescribing information.